StockNews.AI
RVTY
StockNews.AI
139 days

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

1. Revvity receives FDA approval for Auto-Pure 2400 with T-SPOT™.TB test. 2. The platform enhances productivity and clinical performance in TB detection.

FDA Approval
-3.06%Current Return
VS
-3.48%S&P 500
$104.3104/02 08:07 AM EDTEvent Start
$101.11504/03 02:47 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

FDA approval can lead to increased sales and market penetration. Similar approvals in the past have positively impacted biotech stocks.

How important is it?

This approval represents a significant growth opportunity, affecting investor sentiment positively.

Why Short Term?

Immediate revenue generation is expected from this new product launch. Historical cases show short-term stock boosts post-approval.

Related Companies

ABTBAXPCRX
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (TB) detection. This milestone marks a significant advancement in the fight against TB with a faster hig.

Related News